Press Release
Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
“The compelling preclinical results demonstrate the ability to achieve target pharmacokinetic and tolerability objectives for both a single active IVR (DARE-FRT1) and dual active IVR (DARE-HRT1),” said Dr.
The current 505(b)(2) candidates under development, DARE-HRT1 and DARE-FRT1, formerly JNP-0201 and JNP-0301 respectively, were licensed by Daré from
This IVR technology allows for active drug to be homogenized in a solid EVA polymer matrix and eliminates the need for a membrane or reservoir to contain the active drug or control the release. Individual drug segments provide the opportunity for multiple drug and dosage level options. Compared to other drug delivery vehicles, these features provide flexibility to incorporate a wide molecular weight range including poorly bioavailable drugs.
The abstracts will be presented in a poster session by Daré’s Chief Scientific Officer,
Poster Abstract Presentation Details for DARE-HRT1
Date:
Time:
Publication: T1130--12-095
Presentation Type: Poster
Title: Pharmacokinetic and tolerability study of a novel 17β-estradiol and progesterone intravaginal ring in sheep
Poster Abstract Presentation Details for DARE-FRT1
Date:
Time:
Publication: W0930--09-72
Presentation Type: Poster
Title: Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré’s full portfolio of women’s health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to the capabilities of the IVR technology to expand Daré’s ability to identify and meet unmet needs in women’s sexual and reproductive health, and to Daré’s ability to advance the technology into human clinical studies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, and other factors discussed in the "Risk Factors" section of Daré's Report on Form 10-K filed with the
Contacts:
Investors on behalf of Daré
Burns McClellan
abavishi@burnsmc.com
212-213-0006
OR
Media on behalf of Daré
Canale Communications
amanda@canalecomm.com
781-405-8775
Source: Daré
Source: Dare Bioscience, Inc.